Prostate cancer prevention strategies using antiproliferative or differentiating agents

Urology

Volumn 57, Issue 4, 2001, Pages 81-85

  Walczak, Janet ^a,b,c,d   Wood, Hadley ^a,b,c,d   Wilding, George ^a,b,c,d   Williams, Thomas ^a,b,c,d   Bishop, Charles W ^a,b,c,d   Carducci, Michael ^a,b,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Ilex Oncology Inc   (United States)

^d BCI Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYAMINE INHIBITOR; RETINOL; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; VITAMIN D;

APOPTOSIS; CANCER PREVENTION; CELL CYCLE G0 PHASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CYCLOOXYGENASE INHIBITORS; EFLORNITHINE; ENZYME INHIBITORS; HUMANS; MALE; NEOPLASM PROTEINS; PHENYLACETATES; POLYAMINES; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 0034964931     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00947-X     Document Type: Article

References (42)

1. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethulornithine
2. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells
3. Induction of apoptosis in prostate cancer cell lines by the green tea component, (1)-epigallocatechin-3-gallate
4. Prostate cancer chemoprevention by green tea: In vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase
5. Toxicity evaluation of difluoromethylornithine: Doses for chemoprevention trials
6. Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diazridinyl-4,9-diazadodecane, results in therapeutic eficacy and enhanced radiosensitivity of human prostate cancer
7. Effects of methylacetylenic putrescine, an ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines
8. The diagnostic value of erythrocyte polyamines (EPA) in prostatic adenocarcinoma (PA): Apropos of 100 patients
9. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans
10. Imaging prostate derived tumors with PET and N-(3-(18F) fluoropropyl) putrescine
11. Is vitamin D deficiency a risk factor for prostate cancer?
12. Vitamin D and prostate cancer: A prediagnostic study with stored sera
13. Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer
14. 2 vitamin D in relation to prostate cancer: A hypothesis
15. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
16. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3
17. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogues
18. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo
19. Chemopreventive activity of taxmoifen, N-(4-hydroxyphenyl) retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate
20. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
21. 1 alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent
22. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha, 25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells
23. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone
24. Effect of retinoic acid on the growth and morphology of a prostatic adenocarcinoma cell line cloned for the retinoid inducibility of alkaline phosphatase
25. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells
26. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cell
27. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
28. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
29. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
30. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs
31. Phenylbutyrate (PB) has plieotropic effects on gene transcription and inhibits telomerase activity in human prostate cancer
32. Phenylbutarate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB
33. Piroxicam and other cyclooxygenase inhibitors: Potential for cancer chemoprevention
34. Generation of mutagens during arachidonic acid metabolism
35. NSAID-induced polyp regression in familial adenomatous polyposis patients
36. Inhibition of apoptosis during development of colorectal cancer
37. Aspirin and other NSAIDs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis
38. NSAIDs and the microcirculation of the stomach
39. Nonsteroidal antiinflammatory drugs-differences and similarities
40. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
41. Inhibition of human prostate tumor cells invasion through a reconstituted basement membrane by the cyclooxygenase-2-selective inhibitor NS398
42. The effects of sulindac derivatives on human prostate cancer cells